Compare Cassava Sciences Inc (FLNA) vs Centrus Energy Corp (LEU) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

Centrus Energy (LEU) trades at $147.83, down 7.25% today, with a bearish technical signal from moving averages. The stock shows mixed fundamentals with a high P/E of 56.92 but strong recent contract wins, including a $1 billion DOE award for nuclear fuel production. Recent earnings beat expectations in Q1 2026 but missed in prior quarters. Positive news includes inclusion in the S&P SmallCap 600 and a letter of intent with Oklo for HALEU supply.

Outlook is cautiously optimistic due to strategic government contracts and nuclear industry tailwinds, but high valuation and recent earnings misses pose risks. Analyst consensus is a Buy with a $223.14 price target, implying significant upside. Key risks include execution on new contracts and volatility in uranium markets.